was used to study its metabolism in six members from three different families with a known hereditary AT Ill deficiency. Six healthy volunteers served as a control group. Sodium dodecyl sulfate-polyacrylamide gel electro-phoresis (SDS-PAGE) and crossed immunoelectrophoresis (CIE) showed the purified AT Ill to be homogenous. Amino acid analysis of the protein revealed a composition identi-cal to a highly purified internal standard. The specific activity was 5.6 U/mg. Analysis of plasma radioactivity data was performed, using a three-compartment model. Neither plasma disappearance half-times nor fractional A NTITHROMBIN III (AT III) has been shown to be a major inhibitor of activated senine proteases.”2 A high incidence of thromboembolic dise...
Background Protein S, which circulates in plasma in both free and bound forms, is an anticoagulant p...
5We have chosen to use the nomenclature of Briginshaw and Shanberge,4’5 i.e., heparin cofactor A, at...
ABSTRACT We studied patients and their relatives with partial deficiency, approximately 50% of norma...
Life-long symptoms of venous thromboembolism were present throughout five generations in a large Ita...
Antithrombin III concentrates were administered to a patient with hereditary AT III deficiency under...
The cloning of antithrombin III (ATIII) complementary deoxyribonucleic acids and the determination o...
A qualitative defect of antithrombin III (AT III) has been demonstrated over 3 generations in 8 memb...
A radioimmunoassay (RIA) had been developed for the determination of antithrombin III (AT III) in ma...
Four members of an Italian family (two with histories of venous thromboembolism) had a qualitative d...
<p>A) Thrombin inhibitory activity of mutant AT compared with wild type AT. The results plotted are ...
The metabolism of human antithrombin III (ATIII) was studied by using 125I-labelled tracer. The plas...
<div><p>Antithrombin III (AT) is the main inhibitor of blood coagulation proteases like thrombin and...
BACKGROUND: Protein S, which circulates in plasma in both free and bound forms, is an anticoagulan...
Antithrombin III (AT III) plasma levels were investigated in 18 full term neonates and 14 healthy pr...
The molecular basis of hereditary antithrombin (AT) deficiency has been investigated in ten Belgian ...
Background Protein S, which circulates in plasma in both free and bound forms, is an anticoagulant p...
5We have chosen to use the nomenclature of Briginshaw and Shanberge,4’5 i.e., heparin cofactor A, at...
ABSTRACT We studied patients and their relatives with partial deficiency, approximately 50% of norma...
Life-long symptoms of venous thromboembolism were present throughout five generations in a large Ita...
Antithrombin III concentrates were administered to a patient with hereditary AT III deficiency under...
The cloning of antithrombin III (ATIII) complementary deoxyribonucleic acids and the determination o...
A qualitative defect of antithrombin III (AT III) has been demonstrated over 3 generations in 8 memb...
A radioimmunoassay (RIA) had been developed for the determination of antithrombin III (AT III) in ma...
Four members of an Italian family (two with histories of venous thromboembolism) had a qualitative d...
<p>A) Thrombin inhibitory activity of mutant AT compared with wild type AT. The results plotted are ...
The metabolism of human antithrombin III (ATIII) was studied by using 125I-labelled tracer. The plas...
<div><p>Antithrombin III (AT) is the main inhibitor of blood coagulation proteases like thrombin and...
BACKGROUND: Protein S, which circulates in plasma in both free and bound forms, is an anticoagulan...
Antithrombin III (AT III) plasma levels were investigated in 18 full term neonates and 14 healthy pr...
The molecular basis of hereditary antithrombin (AT) deficiency has been investigated in ten Belgian ...
Background Protein S, which circulates in plasma in both free and bound forms, is an anticoagulant p...
5We have chosen to use the nomenclature of Briginshaw and Shanberge,4’5 i.e., heparin cofactor A, at...
ABSTRACT We studied patients and their relatives with partial deficiency, approximately 50% of norma...